Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience


Degertekin B., Demir M., Akarca U. S., Kani H. T., Ucbilek E., Yildirim E., ...More

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.31, no.12, pp.883-893, 2020 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 12
  • Publication Date: 2020
  • Doi Number: 10.5152/tjg.2020.20696
  • Journal Name: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.883-893
  • Keywords: HCV, treatment, direct-acting antiviral, Turkey, SUSTAINED VIROLOGICAL RESPONSE, ACTING ANTIVIRAL THERAPY, HEPATOCELLULAR-CARCINOMA, HCV, INFECTION, RIBAVIRIN, CIRRHOSIS, TURKEY
  • Bursa Uludag University Affiliated: Yes

Abstract

Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population.